Author

E. Laack

Institutions: Heidelberg University, Centre Hospitalier Universitaire de Montpellier, Azienda Ospedaliera San Camillo-Forlanini, Jawaharlal Nehru Cancer Hospital and Research Centre, Hospital Universitario Virgen del Rocío

Observed institutions: Eli Lilly (United States), Heidelberg University, Vienna General Hospital, Centre Hospitalier Universitaire de Montpellier, Azienda Ospedaliera San Camillo-Forlanini, Institute of Oncology Prof. Dr. Ion Chiricuta, Jawaharlal Nehru Cancer Hospital and Research Centre, Hospital Universitario Virgen del Rocío, Yonsei Cancer Hospital, Penn State Cancer Institute, Medical University of Vienna

OpenAlex ID: A5035997227

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)

2009 · C. P. Belani, T. Brodowicz, et al. · Journal of Clinical Oncology · 55

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

2011 · L. G. Paz-Ares, F. De Marinis, et al. · Journal of Clinical Oncology · 19

PARAMOUNT : phase 3 comparant un traitement (ttt) de maintenance par Pemetrexed (Pem) plus soins de support (BSC) versus placebo plus BSC après un ttt d’induction par Pem-Cisplatine (Cispt) dans les CBNPC non épidermoïdes avancés

2011 · J.-L. Pujol, L. Paz-Ares, et al. · Revue des Maladies Respiratoires

Works count: 3

Citation count: 74

H-index: 2

I10-index: 2